drugset / Trial / NCT01766609

Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo

NCT01766609

Phase 2 Unknown 18 enrolled University of British Columbia
RandomizedSingle-groupDouble-blindTreatment

Summary

Vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin. It has a major psychosocial impact on affected patients. There are many treatment modalities available for vitiligo, however, none of them cure the disease. Topical corticosteroids (CS) are the most effective monotherapy for localized vitiligo. Treatment with intralesional corticosteroids (ILCS) is commonly used in many dermatologic conditions. However, there are only a few studies published on the use of ILCS in vitiligo. This is a prospective double-blind randomized clinical trial to assess efficacy and safety of ILCS in the treatment of vitiligo. Four treatment sessions will be done over 4 to 6 months. The investigators will compare intralesional triamcinolone acetonide (active treatment) to normal saline (placebo).

Timeline

Start
2013-01
Primary completion
2015-10
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Acetonide Other / unclassified 2.5 mg/ml Other
Comparator Triamcinolone Acetonide Other / unclassified 5 mg/ml Other

Indications